e-Article
Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials
Document Type
Article
Author
Source
In: SKIN: Journal of Cutaneous Medicine . (SKIN: Journal of Cutaneous Medicine, 2022, 6(2))
Subject
Language
English
ISSN
25741624